TAPUR - Calfa, Carmen
-
Investigator:
Carmen Calfa
Email
Coordinator: Carolina Troche
+1 (305) 2431481
IRB: 20170529
SDG: Breast Cancer
Disease Site(s): Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
Sponsor: ASCO
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"
20201218 - Civantos Jr Francisco
-
Investigator:
Francisco Civantos Jr
Email
Coordinator:
IRB: 20201218
SDG: Head and Neck Cancer
Disease Site(s): Lip, Oral Cavity and Pharynx
Sponsor: NRG
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer - NRG-HN006
Eligibility Criteria - NCT04333537 *This information has been extracted from " www.clinicaltrials.gov"
20200056 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator: Nailet Real Bestard
+1 (305) 2438173
IRB: 20200056
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid
Sponsor: DECIPHERA
Enrolling Sites:
Sylvester
Title: A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"
20201539 - Franzmann Elizabeth
-
Investigator:
Elizabeth Franzmann
Email
Coordinator: Zaida Abreu
+1 (305) 2434243
IRB: 20201539
SDG: Head and Neck Cancer
Disease Site(s): Lip, Oral Cavity and Pharynx
Sponsor: Aveta Biomics
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: An exploratory study to evaluate the safety and effectiveness of APG-157 as neo-adjuvant/Induction therapy for patients with head and neck squamous cell cancer (HNSCC) of the oral cavity
MATCH - Huang, Marilyn
-
Investigator:
Marilyn Huang
Email
Coordinator: Carolina Troche
+1 (305) 2431481
IRB: 20150671
SDG: Gynecologic Cancer
Disease Site(s): Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue
Sponsor: ECOG
Enrolling Sites:
Coral Springs
Deerfield
Gables
Hollywood
Kendall
Plantation
SylvesterTitle: Molecular Analysis for Therapy Choice (MATCH)
Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"
20210067 - Ikpeazu Chukwuemeka
-
Investigator:
Chukwuemeka Ikpeazu
Email
Coordinator:
IRB: 20210067
SDG: Head and Neck Cancer
Disease Site(s): Lip, Oral Cavity and Pharynx
Sponsor: ALX Oncology
Enrolling Sites:
Deerfield
Plantation
SylvesterTitle: A Phase 2 Study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Eligibility Criteria - NCT04675333 *This information has been extracted from " www.clinicaltrials.gov"
VERSATILE - Krill Jackson, Elisa
-
Investigator:
Elisa Krill Jackson
Email
Coordinator: Donald Cantrell II
+1 (305) 2435006 x6-5006
IRB: 20200726
SDG: Head and Neck Cancer
Disease Site(s): Larynx,Lip, Oral Cavity and Pharynx
Sponsor: PDS Biotechnology
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK-RDOTAP/HPV-16 E6 & E7 peptides) and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent and/or Metastatic Head and Neck Cancer and High-risk Human Papillomavirus-16 (HPV16) Infection.
Eligibility Criteria - NCT04260126 *This information has been extracted from " www.clinicaltrials.gov"
PRO-ACTIVE - Landera, Mario
-
Investigator:
Mario Landera
Email
Coordinator:
IRB: 20190863
SDG: Head and Neck Cancer
Disease Site(s): Larynx,Lip, Oral Cavity and Pharynx
Sponsor: PCORI
Enrolling Sites:
Deerfield
Gables
Sylvester
UMHTitle: PRO-ACTIVE: Comparing The Effectiveness of Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer
Eligibility Criteria - NCT03455608 *This information has been extracted from " www.clinicaltrials.gov"
20210501 - Lundy Donna
-
Investigator:
Donna Lundy
Email
Coordinator:
IRB: 20210501
SDG: Head and Neck Cancer
Disease Site(s): Larynx
Sponsor: SCCC
Enrolling Sites:
Sylvester
Title: Evaluation of a Disposable Hands-Free Heat and Moisture Exchanger (HME) valve: The Blom-Singer® SpeakFree? HME Hands Free Valve
CPI-006-001 - Merchan, Jaime
-
Investigator:
Jaime Merchan
Email
Coordinator: Rakhi Modak
+1 (305) 2437387
IRB: 20180279
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue
Sponsor: CP
Enrolling Sites:
Sylvester
Title: CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"
RTX-240-01 - Merchan, Jaime
-
Investigator:
Jaime Merchan
Email
Coordinator: Isabel Fernandez
+1 (305) 2435486
IRB: 20200686
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Multiple
Sponsor: Rubius Therapeutics
Enrolling Sites:
Sylvester
Title: PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB
Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"
20210783 - Nicolli Elizabeth
-
Investigator:
Elizabeth Nicolli
Email
Coordinator:
IRB: 20210783
SDG: Head and Neck Cancer
Disease Site(s): Lip, Oral Cavity and Pharynx
Sponsor: ECOG
Enrolling Sites:
Sylvester
Title: A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
Eligibility Criteria - NCT04671667 *This information has been extracted from " www.clinicaltrials.gov"
20191009 - Pimentel Agustin
-
Investigator:
Agustin Pimentel
Email
Coordinator:
IRB: 20191009
SDG: Pancreatic, Liver, and Related Cancers
Disease Site(s): Bones and Joints,Lip, Oral Cavity and Pharynx
Sponsor: HOOKIPA PHARMA
Enrolling Sites:
Sylvester
Title: A Phase I/II Study of TheraT® Vector(s) Expressing HumanPapillomavirus 16 Positive (HPV 16+) Specific Antigens inPatients with HPV 16+ Confirmed Cancers
Eligibility Criteria - NCT04180215 *This information has been extracted from " www.clinicaltrials.gov"
Tbio-6517-ITu-001 - Pimentel, Agustin
-
Investigator:
Agustin Pimentel
Email
Coordinator: Rakhi Modak
+1 (305) 2437387
IRB: 20200277
SDG: Colorectal Cancer
Disease Site(s): Multiple
Sponsor: TSB
Enrolling Sites:
Sylvester
Title: A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors
Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"
AMC-095 - Ramos, Juan Carlos
-
Investigator:
Juan Carlos Ramos
Email
Coordinator:
IRB: 20160656
SDG: Leukemia, Lymphoma, and Myeloma
Disease Site(s): Anus,Lip, Oral Cavity and Pharynx,Lung,Other Hematopoietic
Sponsor: AMC
Enrolling Sites:
Sylvester
Title: A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"
20191010 - Samuels Stuart
-
Investigator:
Stuart Samuels
Email
Coordinator:
IRB: 20191010
SDG: Head and Neck Cancer
Disease Site(s): Other Skin
Sponsor: MERCK SHARP & DOHME
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma(LA cSCC) (KEYNOTE-630).
Eligibility Criteria - NCT03833167 *This information has been extracted from " www.clinicaltrials.gov"
20191016 - Samuels Stuart
-
Investigator:
Stuart Samuels
Email
Coordinator: Lilly Sanchez
+1 (305) 2430974
IRB: 20191016
SDG: Head and Neck Cancer
Disease Site(s): Lip, Oral Cavity and Pharynx
Sponsor: NRG
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Eligibility Criteria - NCT03952585 *This information has been extracted from " www.clinicaltrials.gov"
20210033 - Samuels Stuart
-
Investigator:
Stuart Samuels
Email
Coordinator:
IRB: 20210033
SDG: Head and Neck Cancer
Disease Site(s): Larynx,Lip, Oral Cavity and Pharynx
Sponsor: NRG
Enrolling Sites:
Sylvester
Title: Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Eligibility Criteria - NCT04533750 *This information has been extracted from " www.clinicaltrials.gov"
EA3163 - Sargi, Zoukaa
-
Investigator:
Zoukaa Sargi
Email
Coordinator: Lilly Sanchez
+1 (305) 2430974
IRB: 20180505
SDG: Head and Neck Cancer
Disease Site(s): Lip, Oral Cavity and Pharynx
Sponsor: ECOG
Enrolling Sites:
Deerfield
Gables
Plantation
SylvesterTitle: EA3163:Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC)
Eligibility Criteria - NCT03493425 *This information has been extracted from " www.clinicaltrials.gov"